The dual inhibition of EGFR and HH pathways by cetuximab and vismodegib in combination with cisplatin and docetaxel decreased the cell proliferation and colony-forming ability of HNSCC cells [187]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.